Skip to main content
. 2019 May 31;9:463. doi: 10.3389/fonc.2019.00463

Figure 5.

Figure 5

BEZ235 supports COMBO in the modulation of cell viability. Cell viability of responsive and resistant cells after 25 μM TMZ, 10 mM MET, COMBO and/or 1 μM BEZ235 in combination with all the drugs. Cell viability was assessed by means of a Trypan blue exclusion test and expressed as the percentage of viable cells after 48 h of treatment under normoxic or hypoxic conditions in U251 (A) and T98 (B) cells. *p < 0.05; **p < 0.01; ***p < 0.001 vs. control cells (i.e., untreated cells. For normoxia, control cells are represented by untreated cells in normoxia and the same normalization was used for experiments in hypoxia). The induction of pro-apoptotic (Bad and Bax) and anti-apoptotic genes (Bcl-2) was analyzed by means of real-time PCR in glioma cells treated with 25 μM TMZ, 10 mM MET, COMBO and/or 1 μM BEZ235 in combination with all the drugs for 48 h under normoxic or hypoxic conditions in U251 (C) and T98 (D) cells. The data were normalized to β-actin and the ΔΔct values were expressed as the ratio between the mean values in the responsive and resistant cells [Fold Of Induction (FOI)]. *p < 0.05; ***p < 0.001 treated vs. control cells. Mean values ± SD of three independent experiments.